BioBlast® - Search
2021EU | EU grants marketing authorisation for Tysabri® SC (natalizumab)April 7, 2021
Biogen announced the EC has granted marketing authorisation for Tysabri® (natalizumab) in a subcutaneous presentation. Tysabri® SC is approved for the treatment of relapsing-remitting multiple sclerosis. |
2020Novartis provides updates on Sandoz biosimilar candidatesNovember 24, 2020
Novartis released its annual report ‘Meet Novartis Management 2020‘. In the report, Novartis announced that GP2411 (biosimilar denosumab candidate) has commenced Ph III trials. Novartis has also indicated it has planned launches for biosimilar adalimumab and natalizumab in 2021-2023 and denosumab in 2024-2026. |
New study demonstrates efficacy of natalizumab in MSSeptember 10, 2020
Neurology Advisor reported a new study indicates that natalizumab may be more effective than fingolimod or BRACETD in reducing relapses in patients with relapsing-remitting multiple sclerosis. |
2019Phase III trials of natalizumab biosimilar commenceNovember 18, 2019
Polpharma commences dosing in Phase III trials of proposed natalizumab biosimilar. |
Details of clinical trials of biosimilar natalizumab candidate publishedOctober 13, 2019
Polpharma publishes details of upcoming phase III clinical trials of biosimilar natalizumab candidate. The study will involve approximately 260 patients with relapsing-remitting multiple sclerosis. |
Pfizer and Polpharma licensing deal for natalizumab biosimilarSeptember 3, 2019
Pfizer and Polpharma announce licensing deal for natalizumab biosimilar. Under the agreement, Polpharma will develop, manufacture and supply the product, while Sandoz will be responsible for commercialisation and distribution.
|
Product specific reports based on extracts from our BioBlast® database
aflibercept | Eylea® | Regeneron
bevacizumab | Avastin® | Roche/Genentech
cetuximab | Erbitux® | BMS/Merck
darbepoetin | Aranesp® | Amgen
denosumab | Prolia®/Xgeva® | Amgen
eculizumab | Soliris® | Alexion
filgrastim (GCSF) | Neupogen® | Amgen
golimumab | Simponi® | Janssen
infliximab | Remicade® | Johnson & Johnson
natalizumab | Tysabri® | Biogen/Elan
omalizumab | Xolair® | Genentech / Novartis
pegfilgrastim | Neulasta® | Amgen
pembrolizumab | Keytruda® | Merck
ranibizumab | Lucentis® | Genentech
rituximab | Rituxan®/MabThera® | Genentech/Biogen
tocilizumab | Actemra® | Roche
trastuzumab | Herceptin® | Roche/Genentech
BioBlast® Editor and Contributing Author

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.